PRISM ALS Initiative Launches to Address Critical Gap in ALS Drug Discovery Through Patient-Derived Stem Cell Models
Key Insights
A new global collaboration between ALS (search) TDI, LifeArc (search), and Axol Bioscience (search) aims to expand access to patient-derived stem cell models that better reflect ALS biological diversity.
The initiative addresses a critical gap where 85% of ALS (search) cases are sporadic, yet most drug discovery relies on models representing rare genetic subtypes.
PRISM ALS (search) will develop standardized iPSC-derived motor neuron models from over 1,800 ALS patients to improve therapeutic testing and reduce clinical trial failures.
The ALS Therapy Development Institute (search) (ALS (search) TDI), LifeArc (search), and Axol Bioscience (search) have launched Patient induced pluripotent stem cell (iPSC)-based Research to Improve Sporadic ALS Modelling (PRISM), a collaborative effort designed to address a fundamental mismatch in amyotrophic lateral sclerosis (search) drug discovery that has contributed to high clinical trial failure rates.
Addressing the Sporadic ALS Model Gap
ALS (search) presents as a heterogeneous disease where 10-15% of cases are linked to inherited mutations, while nearly 85% are sporadic. Despite this distribution, much of ALS drug discovery has relied on models representing a limited number of rare genetic subtypes. This mismatch has constrained target discovery, limited therapeutic testing across patient populations, and contributed to the high failure rate of clinical trials.
"We know that ending ALS (search) will require delivering the right treatments to the right individuals," said Dr. Fernando Vieira, CEO and Chief Scientific Officer at ALS TDI. "By characterizing iPSC-derived motor neurons (search) from sporadic ALS and making these cells broadly accessible, PRISM ALS will facilitate global drug discovery."
Comprehensive Patient-Derived Resource
The stem cells used in PRISM ALS (search) are derived from samples contributed by people living with ALS through ALS TDI's ALS Research Collaborative (ARC) Study, the longest-running longitudinal patient study in ALS. Over more than a decade, ALS TDI has built one of the most comprehensive collections of ALS-specific iPSCs available today, with contributions from more than 1,800 people with ALS who have participated in the ARC Study.
These cells come directly from people living with ALS (search), many of whom also contributed detailed clinical data, creating an unparalleled resource for understanding how the disease behaves and how it may respond to therapy.
Standardized Production and Global Access
PRISM ALS (search) aims to develop, evaluate, and make available a diverse panel of well-characterized, patient-derived induced pluripotent stem cell models that capture both genetic and sporadic forms of ALS. The collaboration will enable standardized production at scale, ensuring quality, consistency, and reproducibility across laboratories.
Sapna Vyas, Head of Scientific Programs at Axol Bioscience (search), explained: "We're delighted to participate in this consortium to develop multiple iPSC-derived end point cell types from sporadic ALS (search) iPSC lines that reflect for the first time, real-world variability across age, sex, and genotype. By leveraging Axol's scalable manufacturing infrastructure, we will facilitate access to standardized iPSC-derived cells that empower researchers to stratify patients, assess subgroup responses to therapies, and reduce late-stage clinical trial failures."
Therapeutic Development Impact
For researchers and drug developers, these standardized, human-relevant models could allow them to better understand disease mechanisms, identify therapeutic targets, and evaluate treatments across distinct biological subtypes. For people living with ALS (search), it means therapies can be developed and tested in models that more closely mirror their own biology, increasing the likelihood that discoveries will translate into meaningful treatments.
Paul Wright, Head of MND (search) at LifeArc (search), added: "Our hope is that the stem cell models we produce can unleash a new generation of treatments that could be effective against this disease by slowing its progression and, ultimately, curing it. We need to do more for people living with MND/ALS (search), and PRISM ALS brings together leading organizations to help make that happen."
The partners aim to ensure that these models become a widely accessible, high-quality resource for researchers in academia and industry who are committed to advancing ALS (search) therapies, with the goal of accelerating progress across the ALS field by providing robust, human-relevant tools that better reflect the biological diversity and complexity of the disease.